Pink Sheet Podcast: More Drug Pricing Legislation, Opioids Guidance Confusion And FDA-Advisory Committee Disagreements
Executive Summary
An analysis of interesting provisions in House and Senate drug pricing legislation, a look at questions related to the US FDA's new benefit-risk assessment guidance for opioids, and discussion of a study of FDA's disagreements with its advisory committees.